
Key Points
- 01AbbVie (ABBV) has filed a U.S. FDA biologics license application for etentamig in relapsed/refractory multiple myeloma
- 02Phase 3 CERVINO showed a 74.0% overall response rate for etentamig vs 45.7% with standard therapies
- 03Etentamig cut the risk of progression or death by 60% compared with standard available therapies
- 04Monthly intravenous dosing with a step-up start aims to offer a convenient treatment schedule
AbbVie files BLA for etentamig in multiple myeloma
AbbVie (ABBV) has submitted a Biologics License Application to the U.S. Food and Drug Administration for intravenous etentamig to treat adults with relapsed or refractory multiple myeloma. The investigational therapy is intended for patients who have already received at least two prior lines of treatment and have been exposed to a proteasome inhibitor, an immunomodulatory drug and an anti‑CD38 monoclonal antibody. The filing seeks approval of etentamig as a treatment option in a setting where available therapies are limited.
Phase 3 CERVINO efficacy results
The BLA is backed by results from the global, multicenter, randomized Phase 3 CERVINO study, which enrolled 393 patients and assigned them 1:1 to etentamig or investigator-selected standard available therapies. Etentamig met both dual primary endpoints in this population of triple-class exposed relapsed or refractory multiple myeloma. The trial showed an overall response rate of 74.0% for etentamig compared with 45.7% for standard therapies. Etentamig also delivered a 60% reduction in the risk of progression or death versus standard available therapies, indicating a statistically significant improvement in progression-free survival.
Investigators described etentamig as a second-generation BCMA-directed bispecific antibody T‑cell engager with a clinical profile designed for use across a broad range of treatment settings, including community-based care. The topline CERVINO results had been disclosed earlier in 2026 and now form the core clinical evidence package for the FDA submission.
Dosing schedule and administration
Etentamig is administered intravenously, beginning with a single step-up dose followed by dosing every four weeks from treatment initiation. This monthly dosing schedule is intended to provide a patient-centered regimen that may be compatible with varied care settings. The clinical data indicate that the therapy can be delivered with this schedule from the outset of treatment.
The monthly dosing approach is highlighted as a potential convenience advantage for people living with multiple myeloma, particularly those receiving care in community practices. The regimen is designed to support ongoing treatment while limiting visit frequency compared with more intensive dosing schedules used by some other advanced therapies.
Safety profile and adverse events
The CERVINO study also characterized the safety profile of etentamig. The most common treatment-emergent adverse events in the etentamig arm, each occurring in at least 25% of patients, included cytokine release syndrome, hypogammaglobulinemia, neutropenia and anemia. Among patients who received a single step-up dose, cytokine release syndrome occurred in 28.3% of patients, with all events limited to grade 1 or grade 2 and no grade 3 or higher cases reported. One patient experienced a grade 1 immune effector cell-associated neurotoxicity syndrome event.
Treatment-emergent adverse events led to discontinuation of etentamig in 3.6% of patients, compared with 14% in the standard-therapy group. Grade 3/4 infections occurred in 27.7% of patients on etentamig versus 19.2% on standard therapies. Grade 5 infections were observed less frequently with etentamig, at 1.5%, compared with 3.1% in patients receiving standard available therapies. Overall, the data support a manageable safety profile in the studied population.
Positioning in relapsed/refractory disease
BCMA-directed bispecific antibodies and CAR‑T therapies have altered the treatment landscape for multiple myeloma but can face constraints such as cytokine release syndrome, infections, neurotoxicity and specialized monitoring requirements. In later lines of therapy, available options remain limited for patients whose disease has relapsed after multiple treatments. AbbVie positions etentamig as a novel T‑cell–engaging antibody that may help address these needs with an intravenous therapy and a monthly dosing schedule.
The CERVINO data package underpins the regulatory bid to introduce this second-generation BCMA-directed bispecific antibody T‑cell engager into clinical practice for adults with relapsed or refractory multiple myeloma. The FDA review of the BLA will determine whether etentamig can be made available as a new option in this setting.
Key Takeaways
- 01AbbVie (ABBV) is seeking U.S. approval of etentamig specifically for adults with relapsed or refractory multiple myeloma after at least two prior treatment lines.
- 02Phase 3 CERVINO results show a substantial efficacy advantage for etentamig over standard available therapies in both response rates and progression-free survival.
- 03Safety data indicate a manageable profile with low discontinuation rates, while still requiring attention to infections and cytokine release syndrome.
- 04The single step-up followed by monthly intravenous dosing is central to etentamig’s proposed use and is intended to fit both specialized and community-based care settings.
- 05The FDA’s decision on this BLA will be pivotal in determining whether etentamig becomes a new BCMA-directed bispecific option in later-line multiple myeloma care.
References
- https://finance.yahoo.com/healthcare/articles/abbvie-submits-biologics-license-application-120000948.html?.tsrc=rss
- https://www.biopharmawatch.com/news/ABBV/abbvie-bla-etentamig-multiple-myeloma
- https://www.stocktitan.net/news/ABBV/abb-vie-submits-biologics-license-application-bla-for-etentamig-to-u-23fcitzyc6pr.html
- https://rallies.ai/news/abbvie-seeks-fda-approval-for-etentamig-to-treat-multiple-myeloma-bc7bdf58acbd3333